Recent News

Can PET/CT Imaging Predict Survival in Multiple Myeloma Relapse?

ASCO 2022: Phase II MagnetisMM-3 Trial Focuses on Elranatamab in Resistant Myeloma

ASCO 2022: Update From Cohort A of CARTITUDE-2 on Ciltacabtagene Autoleucel in Myeloma

ASCO 2022: Ixazomib Plus Daratumumab in Elderly Frail Patients With Resistant Multiple Myeloma

ASCO 2022: Early-Phase Study of Talquetamab in Resistant Multiple Myeloma

ASCO 2022: Daratumumab-Based Therapy for High-Risk Smoldering Myeloma

ASCO 2022: Update From CARTITUDE-1 on Ciltacabtagene Autoleucel in Refractory Myeloma

ASCO 2022: Induction Triplet Regimen With or Without ASCT and Maintenance Therapy for Myeloma

Neuroepigenetic Changes and Their Influence on Bortezomib-Induced Peripheral Neuropathy

MARCH Trial: Selinexor Plus Dexamethasone in Chinese Patients With Resistant Myeloma

Neutralizing Antibody Response After COVID-19 Vaccination: Great Variation Among Patients With Myeloma

Cytogenetic Risk Stratification: A Real-World Approach to Optimizing Outcomes in Myeloma

Does Novel Protein Drive Disease Progression in Multiple Myeloma?

Vaccine Plus Co-stimulated T Cells Under Study in Multiple Myeloma

Can MGUS Status Predict the Progression of Multiple Myeloma?

Predicting Progression of Smoldering Multiple Myeloma With Novel Dynamic Model

AACR 2022: Novel IKZF1/3 Degrader Demonstrates Activity in Multiple Myeloma

AACR 2022: Are Bone-Modifying Agents Equitably Administered to Patients With Myeloma?

AACR 2022: Circulating Tumor DNA Mutations and Relapse in Refractory Myeloma

AACR 2022: Selinexor With or Without Duvelisib Under Study in Multiple Myeloma

AACR 2022: Can Novel CAR T Cells Overcome BCMA Antigen Loss in Myeloma?

AACR 2022: Novel Drug Delivery System Under Study in Multiple Myeloma

Survival Update From ICARIA-MM: Isatuximab Plus Pomalidomide and Dexamethasone in Myeloma

Patient-Driven Data Capture Platform May Enhance Multiple Myeloma Research

Can Gene Expression of Myeloma Cells Differ at the Single-Cell Level?

New miRNA-Targeted Therapies Under Study in Multiple Myeloma

Predictive Genetic Marker for Immunomodulatory Treatment of Multiple Myeloma

Belantamab Mafodotin-blmf in Resistant Multiple Myeloma: From the Mayo Clinic

FDA Brief: BCMA-Targeting Immunotherapy Receives Fast Track Designation in Myeloma

Venetoclax Plus Bortezomib and Dexamethasone in Resistant Myeloma: Final Results From BELLINI Trial

Intensified Daratumumab Combination Therapy Before and After ASCT in Myeloma: UK Trial

Ciltacabtagene Autoleucel Approved by the FDA for Treatment of Resistant Multiple Myeloma

Sec61 Translocon: Novel Therapeutic Target in Multiple Myeloma?

Update From Phase III APOLLO Trial of Daratumumab-Based Therapy for Myeloma

Prognostic Value of the MGUS-Like Phenotype in Multiple Myeloma

Dana-Farber Receives $40 Million Grant to Support Multiple Myeloma Research

FDA Brief: Anti-CD47 Antibody Granted Orphan Drug Designation in Myeloma

Addition of Ixazomib to Maintenance Therapy After Autologous Stem Cell Transplantation in Myeloma

Early-Phase Research on Daratumumab-Based Therapies for Resistant Myeloma

Early-Phase Study of Subcutaneous Talquetamab Plus Daratumumab in Resistant Myeloma

Elotuzumab-Based Therapy Plus Transplantation in Newly Diagnosed Myeloma: Phase III Trial Results

Early Research Findings on Novel Bispecific Monoclonal Antibody in Resistant Myeloma

Racial/Ethnic Differences in Patients With Myeloma: Clonal Hematopoiesis, Tumor Markers, and Outcomes

Phase III GMMG-HD7 Trial: Isatuximab-Based Therapy for Newly Diagnosed Myeloma

Activating T Cells With Talquetamab to Treat Multiple Myeloma

Extended Follow-up With Daratumumab-Based Regimen in Newly Diagnosed Myeloma

First-in-Class Targeted Cellular Therapy Under Study in Resistant Multiple Myeloma